Gastrointestinal Cancer

Al B. Benson, MD, discusses the implications of microsatellite instability testing on patients with colorectal cancer.

David H. Ilson, MD, PhD, discusses remaining challenges with immunotherapy in gastric cancer.

Daniel Catenacci, MD, discusses factors that may guide treatment selection for patients with esophagogastric junction adenocarcinoma.

Manish A. Shah, MD, discusses ongoing efforts to improve immunotherapy in gastric and gastroesophageal junction cancer.

Luke Dow, PhD, discusses the next steps for researching the Wnt pathway in colorectal cancer.

The FDA has scheduled an Oncologic Drugs Advisory Committee hearing for December 17, 2019, to discuss a supplemental new drug application for olaparib tablets as a maintenance treatment of adult patients with deleterious or suspected deleterious BRCA-mutant metastatic pancreatic adenocarcinoma whose disease has not progressed on frontline platinum-based chemotherapy.

Manuel Hidalgo Medina, MD, PhD, discusses treatment considerations in pancreatic cancer.

Ryan B. Corcoran, MD, PhD, discusses promising combination strategies with immunotherapy in metastatic colorectal cancer.

Allyson Ocean, MD, discusses the impact of the phase III PRODIGE 24/CCTG PA.6 trial on patients with pancreatic cancer.

Al B. Benson, MD, professor of medicine, Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses ongoing research with immunotherapy in metastatic colorectal cancer (mCRC).

Innovative clinical trials designed to exploit the explosion of data on the drivers of cancer are demonstrating value as tools to explore potential signals of efficacy across tumor types, according to oncology experts. These studies have become a feature of the drug discovery landscape in oncology and are likely to remain part of the fabric of clinical research in the genomic era.

Recent strides in systemic treatment approaches and the broader application of stereotactic radiation led the American Society for Radiation Oncology to issue its first guideline regarding radiation therapy in patients with pancreatic cancer.

Timil Patel, MD, discusses an optimal sequencing strategy in rectal cancer.

The FDA has granted a priority review to a new drug application for pemigatinib as a treatment for patients with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements.